Search Results

You are looking at 61 - 70 of 691 items for :

  • Refine by Access: All x
Clear All
Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Lisa Gurski, and Deborah A. Freedman-Cass

Guidelines) for Rectal Cancer. These guidelines begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, management of

Full access

John P. Sherbeck, Lili Zhao, and Richard W. Lieberman

The pathologic evaluation of lymph nodes (LNs) for metastatic disease plays an important role in the surgical staging of nearly all solid-organ malignancies. Nodal tissue is evaluated by pathology either as part of an en bloc resection or as

Full access

Kenneth C. Anderson

the NCCN Guidelines is a revised staging system. Traditionally, the International Staging System (ISS) has been used, which is based on serum albumin and beta-2 microglobulin. The Revised ISS uses these factors in addition to serum lactic dehydrogenase

Full access

Presenter: Leo I. Gordon

Driven in part by advances in imaging technology, clinical staging in lymphoma has evolved significantly since the 1970s. At the NCCN 2020 Virtual Congress: Hematologic Malignancies, Leo I. Gordon, MD, Abby & John Friend Professor of Cancer

Full access

Rajmohan Murali, Deborah F. Delair, Sarah M. Bean, Nadeem R. Abu-Rustum, and Robert A. Soslow

data from clinicopathologic and molecular genetic studies, pathology will continue to play a central role in diagnosis, prognostic assessment, and treatment planning. Evolution of Surgical-Pathologic Staging Most patients with endometrial cancer

Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar

available online ( NCCN.org ). Surgical Axillary Staging for Stages I, IIA, IIB, and IIIA (T3N1M0) ALND is the standard of care for patients with clinically positive nodes. However, ALND is associated with lymphedema and other significant morbidities

Full access

Stacey Shiovitz and Keith D. Eaton

interpretation (T1, N1, M-oligo), her case was considered for treatment with curative intent for oligometastatic disease. The TNM staging guidelines for NSCLC were revised recently to account for better-understood prognostication based on disease involvement. 1

Full access

Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Lucille A. Leong, Edward Lin, Michael G. Martin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Deborah A. Freedman-Cass, and Kristina M. Gregory

rectal cancer. These guidelines begin with the clinical presentation of the patient to the primary care physician or gastroenterologist, and go on to address diagnosis, pathologic staging, neoadjuvant treatment, surgical management, adjuvant treatment

Full access

Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Peter E. Clark, Tracy M. Downs, Jason A. Efstathiou, Thomas W. Flaig, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Guru Sonpavde, Jonathan Tward, Geoffrey Wile, Mary A. Dwyer, and Lisa A. Gurski

beyond the scope of these guidelines. Muscle-Invasive Urothelial Bladder Cancer Additional Workup Several workup procedures are recommended to accurately determine clinical staging of MIBC. Laboratory studies, such as a complete blood cell

Full access

Jason P. Wilson, David Mattson, and Stephen B. Edge

trial, combined with the results of the NSABP B-06 trials, changed the standard therapy from radical mastectomy to breast-conserving therapy, with axillary lymph node dissection (AND) performed for staging and local control. 2 In 1994, sentinel lymph